CUMULATIVE INDEX 1996

Volume 25

March	THYROID CANCER II, pages 1–216
June	CHRONIC COMPLICATIONS OF DIABETES, pages 217–490
September	GROWTH AND GROWTH DISORDERS, pages 491–780
December	OBESITY, pages 781–1048

Note: Page numbers of article titles are in **boldface** type.

Abdominal pain, in diabetes, 370
Abdominoplasty, for obesity, 1017
Acanthosis nigricans, in diabetes, 467–468
Accelerated growth, 754, 755, 757
ACE inhibitors, in diabetic nephropathy, 228, 301–302, 404
  in hypertension, 412–416
Acetyl-CoA carboxylase, 850
Acetyl-L-carnitine, for diabetic neuropathy, 343
Achondrogenesis type 1B, 692
Achondroplasia, 687–690, 749
Acquired immunodeficiency syndrome, growth hormone therapy, 765
Acquired perforating elastosis, in diabetes, 468
Acromegaloidism, 644, 653–654
$ACTH_{4-9}$ analogue, for diabetic neuropathy, 343
Activin, 552
Activity monitoring and records, in energy expenditure, 842
Acute lymphoblastic leukemia, chemotherapy in, 735, 736
Acute myocardial infarction, in diabetes, 429–431
Adenosine, in lipolysis, 862
Adhesive capsulitis of shoulder, in diabetes, 476–477, 480
Adipocytes. See *Fat cells.*
Adipose tissue, as secretory organ, 791–792, 932–934
Adipsin, 792
Adolescents. See *Children; Puberty.*
Adoption studies of obesity, 804
Adrenal steroids, in obesity, 794–795
Adrenergic receptors, in lipolysis, 859–861
Advanced glycation/glycosylation end products, in diabetes, 261–263, 285, 315, 339, 481
Advanced growth, 754, 755, 757
AGE, in diabetes, 261–263, 285, 315, 339, 481
Aging, growth hormone secretion in, 555–556
Agouti protein, in obesity, 787–788, 806
AIDS, growth hormone therapy, 765
Airway hyperplasia, asthma-associated, 605–606
AKR/J x SWR/J model of obesity, 808–809
Albuminuria, in diabetes, macroalbuminuria, 299
  microalbuminuria, 222–226, 297–299, 412
  vascular disease and, 440
ALCAR, for diabetic neuropathy, 343
Alcohol, in nutrition planning, 957–958
Aldose reductase inhibitors, for diabetic neuropathy, 342
ALL, chemotherapy in, 735, 736
Allergy, insulin, 470
Alpha-adrenergic receptors, in lipolysis, 860–861
Alpha-lipoic acid, for diabetic neuropathy, 344
Amitriptyline, for pain in diabetic neuropathy, 344–345
Amphetamines, for obesity, 950–951, 995
Amputation, in diabetes, 308–309, 447
Anaplastic thyroid cancer, 61–63
  external beam radiation therapy, 148–150
  fine-needle aspiration, 85–86
  surgical management, 126
Androgens, in obesity, 922–923

Androgens *(Continued)*
in pubertal growth, 671–673
Angelman syndrome, genomic imprinting in, 509–511
Angioplasty (PTCA), in diabetes, 432–433
Angiotensin converting enzyme inhibitors, in diabetic nephropathy, 228, 301–302, 404
in hypertension, 412–416
Animal models of obesity, **781–800,** 806–810
adipose tissue as secretory organ in, 791–792
adrenal steroids in development of obesity, 794–795
AKR/J x SWR/J model, 808–809
BBS model, 808
central nervous system in, 793–794
complex genetic transmission of obesity, 809–810
genetic background in phenotypic expression of obesity syndromes, 790–791
genetics of polygenic obesity, 788–789, 807–808
hyperphagia/autonomic dysfunction in, 792–793
identification of human obesity genes and, 807, 810
in rodents, 806–810
single genes in, 806
agouti protein, 787–788, 806
carboxypeptidase R, 786–787
leptin and leptin receptor, 783–786
tub gene mutation, 788, 806–807
transgenic models, 789–790
types of, 781–783
Anthropometrics, in childhood obesity, 874–876
Anti-CEA antibody, in thyroid cancer imaging, 108–109
Antigenicity of thyroid epithelial cancers, 162–164
Antihypertensive treatment, 412–415
Antilipolytic factors, 861–862
Appetite, exercise and, 970–972
Arthritis, in diabetes, 474
Askanazy (H<um>urthle) cell follicular neoplasms, fine-needle aspiration, 80, 82–83, 88, 89
surgical management, 124–125
Asthma, airway hyperplasia in, 605–606
glucocorticoid therapy in, growth suppression and, 705–710
Ataxia-telangiectasia, 187
Atelosteogenesis type II, 692
Atherosclerosis, in diabetes, contributing factors, 426–429
hypertension and, 402–403
lower extremity, 442
Attenuated growth pattern, 748, 751–754
Autonomic dysfunction, in animal obesity, 792–793
Autonomic neuropathy, in diabetes, 336–337, 416

Baclofen, for pain in diabetic neuropathy, 345
Bacterial infections, in diabetes, 469
Bardet-Biedl syndrome, 803
Basal metabolic rate, in energy expenditure, 837
Basement membrane thickening, in diabetes, 244, 256, 296, 298
BDP, growth suppression from, 707, 708
Beckwith-Wiedemann syndrome, 643, 755
genomic imprinting in, 511–515
Beclomethasone diproprionate, growth suppression from, 707, 708
Behavioral therapy for obesity, **943–954**
effectiveness of, 948–949
historical perspective, 943–944
length of treatment and weight loss, 949–950
pharmacotherapy and, 950–951, 994–995
post-treatment weight gain and, 951–952
strategies, 946
behavioral contracting, 947
philosophy and theory, 944–945
reinforcement, 945–946
self-monitoring, 946–947
social support, 947
stimulus control, 945
weight maintenance, 947–948
very low calories diets and, 950
Benzphetamine, for obesity, 991, 995
Beta-adrenergic receptors, in lipolysis, 859–861
Beta-blockers, in diabetes, in hypertension, 413
in myocardial infarction, 430–431
Biliopancreatic bypass, for obesity, 1010–1011
Biopsy. See also *Fine-needle aspiration of thyroid.*
for diabetic nephropathy, 297–298
Blood pressure. See also *Hypertension.*
body mass index and, 908, 911–913
diabetic nephropathy and, 300–302
diabetic retinopathy and, 220–221
Body composition, in childhood obesity, **871–885**
methods for determining, anthropometrics, 874–876
body potassium, 878
conductivity, 878–879
densitomery, 876–877
dilution techniques, 877–878

dual-energy absorptiometry, 877
imaging, 879
impedance measurement, 878
neutron activation, 879
models of, atomic measurement, 871
cellular model, 872–873
molecular model, 872
tissue model, 873
whole body, 873–874
Body fat. See also *Obesity.*
health hazards of, **907–919**
regional distribution and, 909–910
Body mass index, 802
cutoff points, 888–889
distribution in US adults, 893–895
increases since 1960–1962, 893
mortality and, 908, 994–995
obesity in Europe and, 903
Bombesin, satiation and, 823
Bone(s), irradiation injury, 733
obesity and, 916
thyroid hormone effect on, 720–721
Bone age, 744–745
delayed, diagnostic screening, 752
Bone mineral density, growth hormone and sex steroid hormone effects on, 673–676
thyroid hormone and, in children, 34
Bone mineral loss, in diabetes, 473–474
Boys, bone mineralization in, 674
puberty in, 665, 666
Brain, in food intake, 818–819
glucose and, 325–328
Bromocriptine, prolactin and, 928
Brussels study, 244–245
BSB model of obesity, 808
Budesonide, growth suppression from, 707
Bullae, diabetic, 451, 467
Burns, growth hormone in, 766
insulin-like growth factor I in, 768
Bypass surgery, in diabetes, 433–434

Caffeine/ephedrin, for obesity, 991, 998
Calcitonin measurement, pentagastrin test with, 12–14
Calcium channel blockers, in hypertension, 413, 415, 416
Calorimetry, 837
Camptomelic dysplasia, 693–694
Cancer, as molecular disorder, 159
obesity and, 916
thyroid. See *Thyroid cancer.*
Cancer therapy, growth effects of, **731–741**
Candida infection, in diabetes, 469
CAPD, 310, 311
Capillaries, in diabetes, basement membrane thickening, 244, 256
ischemia and, 440–441
Capsaicin, for pain in diabetic neuropathy, 346
Carbamazepine, for pain in diabetic neuropathy, 345
Carbohydrate, metabolism, growth hormone and, 765, 766
in nutrition planning, 956–957, 959–960
Carboxypeptidase E, in obesity, 786–787
Cardiovascular disease, obesity in, 907–909, 911–913
Carpal tunnel syndrome, in diabetes, 475–476, 480
Catch-up growth, 745
Catecholamines, in growth hormone system axis, 546–547
lipoprotein lipase and, 853
Cathepsins, 604–605
Causalgia, in diabetes, 476–477, 480
CDGA, 670, 671, 672
CDKs, 493–499
Cell cycle, in growth, **493–502**
abnormalities in human disease, 498–499
regulation, cyclins, cyclin-dependent kinase, and inhibitors, 493–494
G_1 phase, 492–493, 494–496
G_2 and M phases, 493, 497–498
S phase, 493, 496–497
Cellular and molecular mechanisms of diabetic complications, **255–270**
Central nervous system, disorders, in diabetes, 325–332
in obesity, 793–794
Central precocious puberty, 671
Cerebral gigantism, 755, 757
Charcot foot, 450
Chemokines, in thyroid cancer, 169
Chemoreceptors, in food intake, 819
Chemotherapy, with external beam radiation therapy, in thyroid cancer, 149, 152
growth effects of, 734–735, 738–739
central, 735–736
distal, 736–737
Chernobyl accident, 199–201
childhood thyroid cancer after, **197–211**
clinical experience and accrual of cancers, 201–205
epidemiology, 205–208
ongoing and future inquiries, 208–209
Children, growth hormone and sex steroid interactions in, 669–670
obesity in, **871–885**
American youth, 879–880
body composition and, 871–879
concepts of, 880
discussion, 882–883
prevalence, 875, 880–882
thyroid cancer in, **27–48, 197–211**
Cholecystokinin, satiation and, 822–823
Cholelithiasis, in obesity, 915

Cholesterol, body mass index and, 908
gallstones and, 915–916
Cholinergic systems, in growth hormone system axis, 547
Chondrocytes, in epiphyseal growth plate, 619–620
Chondrodysplasias, molecular genetics, **683–697**
mutations summarized, 684
Chronic renal failure, growth hormone and, 559, 753, 760–761
Cisapride, for diabetic gastroparesis, 371–374
Clonazepam, for pain in diabetic neuropathy, 345
Clonidine, in diabetes, 345, 374
Coagulation abnormalities, in diabetes, 428–429
COL9A2, 691
COL10A1, 687
COL11A2, 687
COLA2A1, 683, 685–687
Collagen, glucocorticoid therapy and, 703–704
Colony-stimulating factors, in growth without growth hormone syndrome, 658–659
Coma, diabetes and, 328–330
Combined pituitary hormone deficiency, 523–524
COMP, 690
Complete androgen insensitivity, 671
Computed tomography, in childhood obesity, 879
in thyroid cancer, 103, 106
Conductivity, in childhood obesity, 878–879
Congestive heart failure, in diabetes, 404, 434–435
Connective tissue, obesity and, 916
Connective tissue disease, in diabetes, **473–484**
joints, 474–475
pathogenesis, 479, 481
skeleton, 473–474
skin and periarticular tissue, 475–479, 480
Constipation, in diabetes, 369–370, 375
Constitutional delay of growth and adolescence, 670, 671, 672, 747, 750
Continuous ambulatory peritoneal dialysis, in end-stage renal disease, 310, 311
Coronary artery bypass surgery, in diabetes, 433–434
Coronary artery disease, in diabetes. See also *Heart disease.*
epidemiology, 228–235
hypertension and, 403, 414
obesity in, 907–909, 911
Corticosteroids, growth suppression by, **699–717**
Corticotropin-releasing hormone, 547–548
in obesity, 793–794
Cortisol, in obesity, 922
Cowden's syndrome, 59
Cranial irradiation, growth effects of, 732–733, 737
hypothyroidism from, 738
Craniopharyngioma surgery, 644, 649–651
CRH, 547–548
Cushing's syndrome, 745–746
Cyclin-dependent kinase, 493–499
Cyclins, 493–499
Cytokines, in thyroid cancer, 173
in immunotherapy of thyroid cancer, 170, 171
interactions on thyroid cancer cells, 166–170

DAG, in diabetes, 259, 260
Dallas Diabetes Prospective Trial, 246, 247
db gene, 783–787, 806, 807
Debridement of foot ulcers, 453
Delayed growth pattern, 748, 750–751
Denaturing gradient gel electrophoresis, in detection of *RET* mutations, 8, 10
Densitometry, in childhood obesity, 876–877
Dermatologic disorders. See *Skin disorders.*
Dermatophyte infections, in diabetes, 469
Dermatoses, in diabetes, 451
Dermopathy, diabetic, 451, 465–466
Desipramine, for pain in diabetic neuropathy, 345
Dexamethasone, growth suppression by, 703
Dexfenfluramine, for obesity, 951, 991, 997–998
Dextroamphetamine, for obesity, 995
DHT, in pubertal growth, 672
Diabetes Control and Complications Trial, 248–249
Diabetes mellitus, complications, cardiac, **425–438**
cellular and molecular mechanisms, **255–270**
connective tissue and joint disease, **473–483**
dermatologic, **463–472**
epidemiology, **217–242**
foot lesions, 447, 449
heart disease, 228–235, 425–426
kidney disease, 222–228
ocular complications, 218–222, 245–246
foot, **447–462**
gastrointestinal, **361–378**
glucose control and, **243–254**
hypertension, **401–423**

nervous system, **325–359**
ocular, **271–291**
renal, **293–324**
sexual, **379–400**
vascular basis, 255, 283–285
erectile dysfunction, 384–386
growth factors and, 264–266
hyperglycemia-induced mechanisms of dysfunction, 257–264
in lower extremity, **439–445.** See also *Foot lesions.*
in neuropathy, 339–340
pathophysiology, 256–257
vascular disease of lower extremities, **439–445**
hypertension in, epidemiology, 401–402
insulin-dependent, subnormal growth in, 644–645
insulin-like growth factor I in, 768
nephropathy, coronary artery disease and, 233–234
end-stage renal disease, 300, 304–305
alternative strategies to modify course, 315
comorbid index, 315–317
comorbid risk factors, 305–307
rehabilitation, 314–315
therapy, kidney transplantation, 311, 312
maintenance hemodialysis, 310, 311
options, 310, 311
pancreas plus kidney transplantation, 312–313
peritoneal dialysis, 311, 312
survival during, 313–314
epidemiology, 222–228
eye disease and, 307
familial clustering, 294–295
global impact, 293–294
heart disease and, 307–308
hypertension and, 404–405, 415–416
in IDDM, 295, 298–300
limb amputation and, 308–309
neurologic complications, 309–310
in NIDDM, 295, 300
pathology, 296–297
renal biopsy for diagnosis of, 297–298
retarding progression of, by blood pressure normalization, 300–302
by dietary protein restriction, 302–303
by glycemic control, 303
neuropathy, **325–359**
central nervous system, chronic diabetic encephalopathy, 330–331
clinical implications of glucose toxicity to brain, 328
diabetic ketoacidosis and coma, 328–329
glucose and brain, 325–326
hyperglycemia and stroke, 326–328
hyperosmolar nonketotic coma, 329–330
miscellaneous abnormalities, 331–332
gastrointestinal problems and, 361–362
hypertension and, 408, 416
impotence and, 383–384
nephropathy and, 309
peripheral nervous system, 332
classification and clinical characteristics, 332–337
pathogenesis, 337–341
symptom treatment, 344–347
treatment, 341–344
vascular disease and, 441
obesity and, 914–915, 931–932
retinopathy, **271–291**
causes of visual loss, 275–277
epidemiology, 217–222, 271–272
Wisconsin study, 245–246
experimental studies, 282–283
nonproliferative retinopathy, 283–285
proliferative retinopathy, 285–286
grading, 277–279
hypertension and, 405, 408
initial and follow-up ophthalmic evaluations, 279
natural history and pathophysiology, 272–275
nephropathy and, 307
photocoagulation side effects and complications, 281–282
treatment, 279–281
skin disorders in, **463–472**
bullae, 451, 467
dermopathy, 451, 465–466
Dupuytren's disease, 475, 480
foot and leg, 451
infections, 468–469
insulin resistance syndromes, 467–468
necrobiosis lipoidica diabeticorum, 451, 463–465
reactions to treatment, 469–470
scleredema, 466
thick skin, 466–467, 475
yellow skin, 468
Diabetic Retinopathy Study, 280–281
Diarrhea, in diabetes, 364–369, 374–375
Diastrophic dysplasia, 691–692
Diencephalic syndrome, 745
Dietary (animal) models of obesity, 791–793
Dietary therapy for obesity. See also *Nutrition planning in obesity treatment.*
behavioral therapy and, 950
exercise and, 973–978
Diethylpropion, for obesity, 991, 996

Differentiated thyroid cancer, external beam radiation therapy, 141–148
  insular thyroid cancer vs., 55
Dihydrotestosterone, in pubertal growth, 672
Dilution techniques, in childhood obesity, 877–878
Diuretics, in hypertension, 413, 415
DNA binding, Pit–1 and, 526, 528–529
DNA sequencing, for detection of *RET* mutations, 8, 9–10
Domperidone, for diabetic gastroparesis, 371, 373
Dopamine, in diabetes, 331
Dorsalis pedis artery, bypass grafts to, 442
Doubly labeled water, in energy expenditure measurement, 838–841, 966–967
Doxorubicin, with external beam radiation therapy, in thyroid cancer, 149
Drug therapy of obesity. See *Medications for obesity.*
DTDST, 691–692
Dual effector theory of growth hormone action, 619–623
Dual-energy absorptiometry, in childhood obesity, 877
Dupuytren's disease, in diabetes, 475, 480
Dysphagia, in diabetes, 363

Eating behavior, homeostatic feedback models, 815–817
Eating plans, 958–963
Education, patient, for diabetic foot lesions, 458, 459
EGF, in growth without growth hormone syndrome, 658–659
Elderly, growth hormone therapy in, 765–766
Electrophoresis, denaturing gradient gel, in detection of *RET* mutations, 8, 10
Emesis, in diabetes, 363–364
Encephalopathy, in diabetes, 330–331
Endochondral ossification, 615, 619–620
Endocrine changes in obesity, 916
End-stage renal disease, 300, 304–305
  causes, 293
  comorbid index, 315–317
  comorbid risk factors, 305–307
  therapy, 310–315
Energy compensation, exercise and, 970–973
Energy expenditure, **831–846**
  measuring components of, 833
  resting metabolic rate and, 832, 834, 835
  substrate balance in obesity and, 842–843
  thermic effect of food and, 834, 836
  24-hour, measurement of, 833, 836
    by activity monitoring and records, 842
    with doubly labeled water, 838–841, 966–967
    intake/balance method, 841
    with metabolic chambers, 836–838
Energy restriction, exercise and, 973–976
England, overweight prevalence in, 898, 903
Enteropathy. See *Gastrointestinal problems.*
Enterostatin, satiation and, 824
Ephedrine/caffeine, for obesity, 991, 998
Epidemiology of obesity. See *Prevalence of obesity.*
Epidermal growth factor, in growth without growth hormone syndrome, 658–659
Epiphyseal growth plate, 615, 619–620
Epithelial membrane antigen, in thyroid cancer, 165
Erectile dysfunction, in diabetes, **379–400**
  diagnosis, 387–388
  erection physiology and, 380–382
  pathophysiology, 382
    endocrinologic, 386–387
    neurogenic, 383–384
    vasculogenic, 384–386
  penis anatomy and, 380
  treatment, hormonal, 388–389
    nonhormonal, 388
    options, 388
    penile prosthesis, 392–394
    vacuum erection devices, 389
    vascular surgery, 394
    vasoactive agents, intracavernosal injection, 389–392
Erg–1, insulin and, 641–642
Erythromycin, for diabetic gastroparesis, 371–374
Esophageal symptoms, in diabetes, 363, 371
Estrogens, lipoprotein lipase and, 853–854
  in pubertal growth, 671, 673
Europe, overweight prevalence in, 898–901, 903
Exercise, diabetic foot and, 457
  growth hormone secretion in, 557
  as obesity treatment, **965–988**
    for initial weight loss, 968–976
    muscle and metabolic fitness and, 978–981
    in prevention, 966–967
    type, amount, and frequency, 981–983
    for weight loss maintenance, 976–978
External beam radiation therapy, in thyroid cancer, **141–157**
  in anaplastic thyroid cancer, 148–150
  complications, 155
  in differentiated thyroid cancer, 141–148

in medullary thyroid cancer, 150–151
in metastatic disease, 153, 155
in thyroid lymphomas, 151–153, 154
Eye disease, in diabetes. See *Retinopathy.*

fa gene, 783–785
Fairbanks multiple epiphyseal dysplasia, 690
Familial adenomatous polyposis, 59–61
Familial intrinsic shortness, 747
Family studies of obesity, 803–804
Fat, body. See also *Obesity.*
health hazards of, **907–919**
regional distribution and, 909–910
in nutrition planning, 957, 960
Fat cells, **847–870**
lipogenesis and, 847–848
fatty acid–binding proteins, 855
fatty acid uptake, 851–855
glucose metabolism, 850–851
glucose uptake, 848–850
triglyceride synthesis, 856–857
lipolysis and, hormone-sensitive lipase, 857–858
regulation, 858–862
fat gene, 786–787, 806, 807
Fatty acid–binding proteins, 855
Fatty acids, in food intake, 820–821
free, lipoprotein lipase and, 853
in obesity, 933–934
uptake of, 851
lipoprotein lipase activity regulation and, 851–854
LPL gene and, 854–855
Fatty acid synthase, 850
Fatty acid uptake, 851–855
FDG, in thyroid cancer, 101–102
Fenfluramine, for obesity, 951, 991, 993, 997–1000
prolactin and, 928
Fertility, growth hormone and, 765
Fetal growth, insulin in, 637–643
FGF, in growth without growth hormone syndrome, 658–659
FGFR3, 687–690
Fiber, in nutrition planning, 956–957, 960
Fibrinolysis abnormalities, in diabetes, 428–429
Fibroblast growth factor, in growth without growth hormone syndrome, 658–659
Fine-needle aspiration of thyroid, **69–91**
in anaplastic carcinoma, 85–86
equipment, 70
in follicular neoplasm, 79–80, 81
Hürthle cell type, 80, 82–83
in malignant lymphoma, 86, 87, 88
in medullary carcinoma, 83–85
in metastatic carcinoma, 86–89
for nodules in children, 29–30
in papillary carcinoma, classic, 73–77
cystic, 77, 78–79
follicular variant, 77, 79, 80
in small cell carcinoma, 86
technique, 70–72
in thyroid nodule evaluation, 117–119
value, 69–70
Fingers, in diabetes, joint contracture, differential diagnosis, 479, 480
thick skin, 466–467
Fitness, metabolic, exercise and, 979–981
Flexor tenosynovitis, in diabetes, 476, 480
Fluorine-18-fluorodeoxyglucose, in thyroid cancer, 101–102
Fluoxetine, for obesity, 991, 998
Flutamide, 673
Focal neuropathies, in diabetes, 335
Follicular thyroid neoplasm, external beam radiation therapy, 145
fine-needle aspiration, 79–80, 81, 87
Hürthle cell type, 80, 82–83, 88, 89
surgical management, 121–123
Food, thermic effect of, 834, 836
Food intake and exercise, 970–972
Food intake control, **815–829**
homeostatic feedback theories of ingestive behavior, 815–817
putative signals for hunger, satiation, and satiety, 817
distention in gatsrointestinal tract, 818–824
sensory feedback, 817–818
Foot lesions, in diabetes, 384, **447–462**
deformities, 449–450
dermatologic, 451
epidemiology, 447, 449
exercise and, 457
gangrene of toes, 450–451
heel, 449
inspection, 458
ischemia and, **439–445**
pathogenesis, 448
patient education/instructions, 458, 459
prevention, 308–309
team approach, 457–458
ulcer management, 452–455
post-healing, 456
topical treatment, 455–456
wound healing impediments, 457
Formula diets, 961–962
France, overweight prevalence in, 899–900, 903
Fröhlich's syndrome, 650
Frozen shoulder, in diabetes, 476–477, 480

G_1 phase of cell cycle, 492–493, 494–496

G_2 phase of cell cycle, 493, 497–498
GADPH, insulin and, 641–642
Galanin, hunger and, 824
Gallbladder disease, in obesity, 915–916
Gallium imaging, in thyroid cancer, 100–101, 105
Gallstones, cholesterol and, 915–916
Gamma-linolenic acid, for diabetic neuropathy, 343
Ganglioside, for diabetic neuropathy, 342–343
Gangrene of toes, 450–451
Gardner's syndrome, 59–61
Gastric balloon, for obesity, 1015–1016
Gastric bypass, for obesity, 1011–1013
Gastrointestinal problems, in diabetes, **361–378**
  future perspective, 375–376
  manifestations and investigation, chronic abdominal pain, 370
    constipation, 369–370
    diarrhea, 364–369
    dysphagia and heartburn, 363
    nausea and vomiting, 363–364
  pathogenetic mechanisms, abnormal mucosal fluid absorption, 362
    abnormal mucosal sensation, 363
    motor dysfunction, 361–362
  treatment, constipation and incontinence, 375
    diarrhea, 374–375
    esophageal symptoms, 371
    gastroparesis, 371–374
Gastrointestinal tract, distention of, in eating behavior, 818–824
Gastroparesis, in diabetes, 309–310, 371–374
Gastroplasty, for obesity, 1013–1014
Genetic mutations in radiation-induced thyroid cancer, 187–188
Genetics, of chondrodysplasias, **683–697**
  of diabetic nephropathy, 294–295
  of hypertension in diabetes, 402
  of obesity, **801–813**
    adoption studies, 804
    animal models, genetic background in phenotypic expression of obesity syndromes, 790–791
      polygenic obesities, 788–789
      single genes, 783–788
      transgenic models, 789–790
    conclusions from study of human obesity, 805–806
    family studies, 803–804
    linkage and association analyses and candidate genes, 805
    obesity syndromes, 803
    phenotype, 802
    segregation analysis, 804–805
    twin studies, 803
  Pit–1 in gene expression of growth hormone, prolactin, and thyrotropin, **523–540**
  in resistance to thyroid hormone, 723
Genetic screening in thyroid cancer, **1–26**
  mangement of medullary thyroid carcinoma and, 13–20
  RET proto-oncogene and, 2–7
  molecular techniques for detection, 7–13
Gene transfer methods, in thyroid cancer, 171
Genomic imprinting, in growth disorders, **503–521**
  in Beckwith-Wiedemann syndrome, 511–515
  definition, 503
  evidence of occurrence, 504
  identification of imprinted genes, 505–508
  mechanism, 504–505
  in Prader-Willi and Angelman syndromes, 509–511
  in Russell-Silver syndrome, 515
GH. See *Growth hormone.*
GH gene, Pit–1 interactions on, 529–531
GHBP, 545
GHF–1. See *Pit–1.*
GH insensitivity syndrome, 766
GHRD, 623–626
GH receptor gene, 767
GHRH. See *Growth hormone–releasing hormone.*
Girls, bone mineralization in, 674–676
  puberty in, 665, 666, 674
Gliomas, hypothalamic-chiasmatic, 734
Glomerular basement membrane thickening, in diabetes, 296, 298
Glomerular filtration rate, in diabetes, 298, 299, 301–303
Glomerulosclerosis, in diabetes, 296
Glucagon, satiation and, 823–824
Glucocorticoids, in obesity, 793–795, 852–853, 922
Glucocorticoid therapy, growth suppression by, **699–717**
  in cancer treatment, 736–737
  detection and potential treatment, 710–713
  inhaled corticosteroids, 705–710
  mechanisms, 699–705
Glucose, brain and, 325–328
  control. See *Glycemic control; Hyperglycemia.*
  growth hormone secretion and, 557
  metabolism, 850–851
  uptake, 848–850
Glucostatic theory of food intake, 819–820
Glycemic control. See also *Hyperglycemia.*
  in diabetic nephropathy, 303

hypertension and, 412
studies, **243–254**
Glycerol, in food intake, 820–821
GnRH, 547–548
Goiters, multinodular, fine-needle aspiration in, 88, 89
Gonadal damage, from irradiation and chemotherapy, 737–738
Gonadal steroid hormones, 666
Gonadotropin-releasing hormone, 547–548
Granuloma annulare, in diabetes, 465
Graves' disease, thyroid cancer and, 43
Growth, insulin-like growth factors and, **573–614**
mammalian cell cycle in, **491–502**
normal postnatal, patterns of, 743–745
at puberty, 665
Growth disorders, classification, 745–747
diagnosis, **743–758**
excessive linear growth, 754–757
pitfalls, 747
short stature, 747–754
genomic imprinting in, **503–521**
glucocorticoid suppression of growth, **699–717**
irradiation and chemotherapy in, **731–741**
mammalian cell cycle in, **491–502**
molecular genetics of chondrodysplasia, **683–697**
Pit-1 and, **523–540**
thyroid hormone in, **719–730**
Growth factors, in diabetes, neuropathy and, 343–344
retinopathy and, 285–286
vascular dysfunction and, 264–266
insulin as growth factor, **633–647**
Growth hormone(s), chemotherapy effects on, 735–736
contribution to growth, **615–631**
dual effector theory of action, 619–623
IGFBPs and regulation of GH-IGF axis in postnatal growth, 623–626
somatomedin hypothesis, 617–619
deficiency, 557–558
adult, growth hormone therapy in, 764–765
attentuated growth pattern and, 751–754
diagnosis, 753–754
excess, 558–559
gene expression, Pit-1 and, 523–525, 527–530
glucocorticoid therapy and, 701–702, 703
growth without growth hormone syndrome, 644, **649–663**
lipoprotein lipase and, 853
in obesity, 924–927
radiotherapy effects on, 731–733
resistance, in malnutrition, 737
secretion, **541–571**
disorders, 557–561
normal events modulating patterns of, 552–557
physiology, 541–548
by somatotroph, cellular physiology, 548–552
sex steroid interactions with, in bone mineralization, 673–676
clinical observations, 670–671
in infancy and childhood, 669–670
in puberty, 670
role of androgens versus estrogens, 671–673
therapeutic uses, 759–760
chronic renal failure, 760–761
metabolic effects, 764–766
non–growth hormone deficient short stature, 761, 763–764
Turner syndrome, 761
thyroid hormone and, in bone development, 721
in treatment of glucocorticoid-induced growth failure, 710–713
Growth hormone–binding protein, 545
Growth hormone factor–1. See *Pit–1*.
Growth hormone/insulin-like growth factor-I axis, 666–669
androgen and estrogen effects on, 671–673
in postnatal growth, 623–626
Growth hormone receptor deficiency (GHRD), 623–626
Growth hormone–releasing hormone, 543
deficiency, 557–558
effects on somatotroph, 548–551
excess, 558–559
Growth hormone system axis, 541–542
feedback systems, 545–546
hypothalamus, 543–544
neurotransmitters, 546–547
peripheral tissues, 545
pituitary, 544–545
pituitary adenylate cyclase–activating polypeptide, 548
thyrotropin-releasing hormone, corticotropin-releasing hormone, and gonadotropin-releasing hormone, 547–548
Growth without growth hormone syndrome, 644, **649–663**
clinical situations associated with, acromegaloidism, 653–654
following craniopharyngioma surgery, 649–651
human fetal life, 654–655
obesity, 655–656
otherwise normal children, 653
sellar, suprasellar, and hypothalamic disorders, 651, 653

Growth without growth hormone syndrome *(Continued)*
proposed mechanisms, 656
growth hormone variants, 657–658
insulin, 656–657
insulin-like growth factors, 657–658
peptide growth factors, 658–659
pituitary-derived chondrocyte growth factor, 658
prolactin, 657
unidentified serum factors, 659
Gut-brain peptides, in growth hormone system axis, 547

H19 gene, in Beckwith-Wiedemann syndrome, 513–515
Hands, stiff hand syndrome, in diabetes, 477, 480
Harvard University Alumni Study of overweight, 897–898
Hashimoto's thyroiditis, fine-needle aspiration in, 88, 89
Health hazards of obesity, **907–919**
Heartburn, in diabetes, 363
Heart disease, in diabetes, **425–438**
acute myocardial infarction, course and prognosis, 429–430
management, 430–431
atherogenesis and thrombogenesis, coagulation/fibrinolysis abnormalities and insulin, 428–429
lipid abnormalities, 426–427
platelet abnormalities, 427–428
congestive heart failure, 404, 434–435
coronary artery disease, 228–235, 403, 414
epidemiology, 228–235, 425–426
hypertension and, 404–405, 414
nephropathy and, 307–308
revascularization strategies, 432–434
silent ischemia, 431–432
obesity in, 907–909, 911
Heels, in diabetes, 449
Height abnormalities, shortness, 747–754
tallness, 754–757
Hemodialysis, maintenance, 310, 311
Heparin, lipoprotein lipase and, 851
Hirschsprung's disease, *RET* proto-oncogene mutations in, 6
HLA associations with thyroid cancer, 161
Holland, overweight prevalence in, 898–899, 903
Homeostatic feedback models of eating, 815–817
Homocystinuria, 755
Hormone-sensitive lipase, 857–859
HSL, 857–858

Hunger, putative signals for, 817–824
Hürthle cell follicular neoplasms, fine-needle aspiration, 80, 82–83, 88, 89
surgical management, 124–125
Hydrocortisone, growth suppression by, 704
3-Hydroxybutyrate, in food intake, 820–821
Hyperandrogenism, obesity and, 922–923
Hyperglycemia, coronary heart disease and, 232–233
diabetic retinopathy and, 219–220
glucose control studies, **243–254**
microalbuminuria and, 224–225
stroke and, 326–328
in vascular dysfunction, 257–264
Hyperinsulinemia, in obesity, 915, 928–932
Hyperosmolar nonketotic coma, in diabetes, 329–330
Hyperostosis, in diabetes, 474
Hyperphagia, in animal obesity, 792–793
Hypertension, body mass index and, 908, 911–913
in diabetes, **401–423**
epidemiology, 401–402
evaluation, 411–412
in IDDM, 412–414
macrovascular disease and, 402–404
mechanisms, 408–411
microvascular complications, 404–408
nephropathy and, 300–302, 415–416
neuropathy AND, 416
in NIDDM, 414–415
retinopathy and, 220–221
treatment, 412–416
Hypochondroplasia, 688–689
Hypogonadism, from chemotherapy, 738
in diabetes, 386
from radiotherapy, 737
Hypopituitarism, 524–525. See also *Pit–1*.
Hypothalamic-chiasmatic glioma, 734
Hypothalamus, in growth hormone system axis, 543–544
Hypothyroidism, diagnosis, 745–746
from radiotherapy, 738I

IDDM. See *Insulin-dependent diabetes mellitus*.
IGFBPs. See *Insulin-like growth factor binding proteins*.
IGF2 gene, in Beckwith-Wiedemann syndrome, 512–515
IGFs. See *Insulin-like growth factors*.
IL. See *Interleukin* entries.
Imaging, in childhood obesity, 879
in thyroid cancer, **93–113**
evaluation of radiation-induced thyroid cancer, 189–190

medullary thyroid cancer, 106–110
nonisotopic, 102–104
nuclear medicine studies, 93–102, 105
thyroid nodule evaluation, 117
Immune surveillance, in thyroid cancer, 160
Impedance measurement, in childhood obesity, 878
Impotence. See *Erectile dysfunction.*
Incontinence, in diabetes, 375
Infancy, growth hormone and sex steroid interactions in, 669
Infections, in diabetes, cutaneous, 468–469
lower extremity, 453–454
nervous system, 332
Infertility, growth hormone therapy, 765
Inhaled corticosteroids, growth suppression from, 705–710
Insular thyroid cancer, 53–56
Insulin, action of, mechanism, 635–637
physiology, 633–635
in diabetes, 915
heart disease and, 428–429
hypertension and, 409–411
in vascular dysfunction, 264–266
fatty acid synthase and, 851
in food intake, 820, 821
glucose transporters and, 849
as growth factor, **633–647**
early fetal growth, 637
evidence summarized, 634
late fetal growth, 638–643
postnatal growth, 644–645
in growth without growth hormone syndrome, 644, 656–657
in lipolysis, 861–862
Insulin-dependent diabetes mellitus, epidemiology of complications, coronary artery disease, 230, 233
nephropathy, 222–224, 226–227
retinopathy, 218, 221–222
hypertension in, 401–402, 412–414
NIDDM versus, 293–294
nephropathy in, 295, 304–305
renal involvement in, 298–300
subnormal growth in, 644–645
Insulin-like growth factor I, in diabetes, 264–265, 344
glucocorticoid therapy and, 702–703
in growth, **759–773**
in growth without growth hormone syndrome, 657
in obesity, 924–927
therapeutic uses, 769
as anabolic agent, 768
growth-related uses, 766–767
thyroid hormone and, 721
Insulin-like growth factor II, in growth, **759–773**
in growth without growth hormone syndrome, 657
Insulin-like growth factor binding proteins, **591–614,** 615–616
biochemistry, molecular biology, and regulation, 595–598
evolutionary and physiologic aspects, 594–595
functions, IGFBPs with IGF-independent function, 602
inhibition of insulin-like growth factor actions, 598–600
stimulation of insulin-like growth factor actions, 601–602
in postnatal growth, 623–626
proteases, 602–603
cathepsins as, 604–605
effects on IGF-IGFBP axis, 605–608
kallikrein-like, 603–604
matrix metalloproteinases as, 605
in serum, 592–594
Insulin-like growth factor receptors, 577–578
ablation of IGF and IGF receptor expression by homologous recombination, 581–585
Insulin-like growth factors, in growth, **573–590,** 675–676
ablation of IGF and IGF receptor expression by homologous recombination, 581–585
autocrine/paracrine action, 619–623
axis components, 592
chemotherapy and, 736–737
endocrine action, 617–619
in fetal life, 654–655
IGF-overexpressing transgenic mice, 585–586
insulin-like growth factor binding proteins inhibiting, 598–600
insulin-like growth factor binding proteins stimulating, 601–602
mechanisms of action, 577–579
physiology, 574–576
regenerative growth and, 586–587
regulation of expression and action, 576–577
in serum, 592–593
structure and molecular biology, 574
tumorigenesis and, 587
types of actions, 580–581
Insulin receptor, 635–636, 645
Insulin resistance, in obesity, 928–932
syndromes, in diabetes, 467–468
type A, with acromegaloid features, 644
Insulin treatment, complications, 470
Intake/balance method of energy expenditure measurement, 841
Interferons, in thyroid cancer, 168, 173
Interleukin 1, in thyroid cancer, 167–168, 173
Interleukin 2, in thyroid cancer, 168, 170, 171, 173

Interleukin 6, in thyroid cancer, 169, 173
Interleukin 8, in thyroid cancer, 169, 173
Interleukins, in growth without growth hormone syndrome, 659
Intracavernosal injections, for erectile dysfunction, 389–392
Intrauterine growth retardation, 749
Intrinsic shortness, 747–748, 749–750
Intrinsic tallness, 754–755
Iodine 123, 95. See also *Radioactive iodine imaging.*
Iodine 131, in pediatric thyroid cancer, 32, 34–35
  follow-up scans, 38
  risks, 35–37, 198–199
  in thyroid cancer imaging, 95–96. See also *Radioactive iodine imaging.*
Iodine–131 MIBG, in thyroid cancer imaging, 107, 109
Ionizing radiation. See *Radiation exposure.*
Irradiation. See also *External beam radiation therapy; Radioactive iodine ablation.*
  growth effects of, 737–739
    central, 731–733
    peripheral, 733–734
Ischemia, in diabetes, silent, 431–432
  vascular disease and, **439–445**
Ischemic-hypoxic hypothesis, in diabetic neuropathy, 339–340
Italy, overweight prevalence in, 900–901, 903

Jansen metaphyseal chondrodysplasia, 672
Jaw wiring, for obesity, 1016
Jejunoileal bypass, for obesity, 1006–1010
Joint disease, in diabetes, 474–479, 480
Joints, obesity and, 916

Kallikrein-like insulin-like growth factor binding protein proteases, 603–604
Ketoacidosis, diabetic, coma and, 328–329
Kidney disease. See *Nephropathy.*
Kidney transplantation, 311, 312–313
KIP2 gene, in Beckwith-Wiedemann syndrome, 515
Kneemometry, 708
Kniest dysplasia, 685, 686

Laboratory studies of radiation-induced thyroid cancer, 189
Lactic acidosis, in diabetes, 328
LAK cells, in thyroid cancer, 171
Laryngeal nerve, in thyroidectomy, 129–131
Laser photocoagulation, for diabetic retinopathy, 280–282
LDL cholesterol, in diabetes, 426–427
Lep gene, 807
Leprechaunism, 645
Leptin and leptin receptor, in obesity, 783–786, 821–822, 932
Leu–7, in thyroid cancer, 166
Leukemia, chemotherapy in, 735, 736
Leukotriene D_4, 605–606
LH, in puberty, 666
Lidocaine, for pain in diabetic neuropathy, 345–346
Limb amputation, in diabetes, 308–309, 447
Linkage analysis, in obesity, 805
Lipectomy, for obesity, 1016, 1017
Lipids, in diabetes, 403, 426–427
  metabolism, growth hormone and, 765
Lipodystrophy, from insulin, 470
Lipogenesis, fatty acid–binding proteins in, 855
  fatty acid uptake in, 851–855
  glucose metabolism in, 850–851
  glucose uptake in, 848–850
  triglyceride synthesis in, 856–857
Lipoic acid, for diabetic neuropathy, 344
Lipolysis, adrenergic receptors in, 859–861
  antilipolytic factors in, 861–862
  hormone-sensitive lipase in, 857–859
  regulation, 858–859
Lipoprotein(a), in diabetes, 426–427
Lipoprotein lipase, activity regulation, 851–854
Lipostatic theory of food intake, 820–822
Liposuction, for obesity, 1017
Liquid formula diets, 961–962
Liver, in food intake, 819
Lobectomy. See also *Thyroid cancer, surgery.*
  in pediatric thyroid cancer, 32, 35
Low calorie diets, 958
Low-density lipoprotein cholesterol, in diabetes, 426–427
Lower extremity vascular disease, in diabetes, **439–445.** See also *Foot lesions.*
LPL gene, 852, 854–855
Luteinizing hormone, in puberty, 666
Lymph node dissection, in thyroid cancer, 123–124
  in children, 32
Lymphokine activated killer cells, in thyroid cancer, 171
Lymphokines. See *Cytokines.*
Lymphoma of thyroid, 63–65
  external beam radiation therapy, 151–153, 154
  fine-needle aspiration, 86, 87, 88, 89
  surgical management, 127

M phase of cell cycle, 493, 497–498

MacFee incision, 132
Mac–25 gene, 598
Macroalbuminuria, in diabetes, 299
Macrosomia, insulin and, 642–643
Macular edema, in diabetes, 275, 279
Magnetic resonance imaging, in childhood obesity, 879
  in thyroid cancer, 104, 106
Male Turner's syndrome, 749
Malnutrition, growth hormone and, 560, 561, 737
MALT lymphomas of thyroid, external beam radiation therapy, 153
Mammalian cell cycle. See *Cell cycle.*
Marfan's syndrome, 755
Matrix metalloproteinases, in pregnancy, 608
Matrix metalloproteinases, as insulin-like growth factor binding protein proteases, 605
Mauriac syndrome, 644
Mazindol, for obesity, 991, 996
MED, 690–691
Medications for obesity, **989–1004**
  behavioral therapy and, 950–951
  challenges in, 990, 992
  changing attitudes toward, 992, 994
  combinations of drugs, 998–1000
  future directions, 1001, 1003
  selecting patients for pharmacobehavioral therapy, 994–995
  specific agents, 991
    amphetamines, 950–951, 995
    ephedrine/caffeine, 998
    fenfluramine and dexfenfluramine, 997–998
    fluoxetine, 998
    noradrenergic agents, 996
    orlistat, 1001
    phenylpropanolamine, 996
    sibutramine, 1001, 1002
  for weight loss maintenance after modified fast, 1001
Medullary thyroid carcinoma, in children, 39–41
  external beam radiation therapy, 150–151
  fine-needle aspiration, 83–85
  genetic information and clinical management, 13–14
    apparent case of sporadic carcinoma, 16–17
    counseling, 17–18
    families with proven germline transmission, 15–16
    improving cure rate, 14
    thyroidectomy, 18–20
  genetic testing errors in, 11–13
  imaging, 106–110
  RET proto-oncogene and, 2–4, 5
    molecular techniques for detection of mutations, 7–11
  surgical management, 125–126
MEN 2. See *Multiple endocrine neoplasia type 2.*
Mesangial cells, in diabetes, 257
Metabolic chambers, in energy expenditure measurement, 836–838
Metabolic fitness, exercise and, 979–981
Metabolic uses of growth hormone, 764–766
Metabolism. See also *Energy expenditure.*
  adipose tissue, **847–870**
  glucose, 850–851
  growth hormone secretion and, 557
Metaiodobenzylguanidine, in thyroid cancer imaging, 107, 109
Metaphyseal chondrodysplasia, Jansen type, 672–673
Metastasis from thyroid cancer, external beam radiation therapy, 153, 155
Metastatic carcinoma to thyroid, fine-needle aspiration, 86–89
Methylation, in genomic imprinting, 505
Methylation assay, in Prader-Willi and Angelman syndromes, 511
Metoclopramide, for diabetic gastroparesis, 371, 372
Mexiletine, for pain in diabetic neuropathy, 346
MIBG, in thyroid cancer imaging, 107, 109
Microalbuminuria, in diabetes, 222–226, 297–299, 412
Molecular and cellular mechanisms of diabetic complications, **255–270**
Molecular detection of *RET* mutations, 7–13
Molecular genetics. See *Genetics.*
Monitoring, in obesity therapy, 946–947
Morbidity, obesity and central fat and, 910–917
Mortality, effects of obesity, fat distribution, and weight gain on, 907–910, 994–95
Motor neuropathies, in diabetes, 334–335
MTC. See *Medullary thyroid carcinoma.*
Mucormycosis, in diabetes, 332
Mucosa, in diabetes, 362–363
Mucosa-associated lymphoid tissue, thyroid lymphomas from, external beam radiation therapy, 153
Multiple endocrine neoplasia type 2, 1–2, 39–41
  clinical management, 19
  genetic counseling, 17–18
  genetic testing errors, 11–13
  RET proto-oncogene and, 2–7
    molecular techniques for detection of mutations, 7–11
Multiple epiphyseal dysplasia, 690–691

Muscle fibers, exercise and, 978–979
Muscles, obesity and, 916
Myocardial infarction, in diabetes, 429–431
Myopia, diabetic retinopathy and, 221

NADH/NAD+ ratio, in diabetes, 258–259, 284
National Health and Nutrition Examination Survey, overweight in, 875, 880, 881–882, 890–897, 902
National Health Examination Survey, overweight in, 875, 891
Nausea, in diabetes, 363–364
Necrobiosis lipoidica diabeticorum, 451, 463–465
Neonates, growth hormone and sex steroid interactions in, 669
Nephropathy, diabetic, **293–324**
Nesidioblastosis, 643
The Netherlands, overweight prevalence in, 898–899, 903
Neuroendocrine (animal) models of obesity, 793–795
Neuropathy, diabetic, **325–359**
Neuropeptide Y, hunger and, 824
  in lipolysis, 862
Neurotransmitters, in growth hormone system axis, 546–547
  noncholinergic, in erections, 381–382
Neutron activation, in childhood obesity, 879
NHANES, overweight in, 875, 880, 881–882, 890–897, 902
NHES, overweight in, 875, 891
NIDDM. See *Non–insulin dependent diabetes mellitus.*
Non–insulin dependent diabetes mellitus, epidemiology of complications, coronary artery disease, 231, 233, 234–235
  nephropathy, 226–227
  retinopathy, 221–222
  hypertension in, 401–402, 414–415
  IDDM versus, 293–294
  in nephropathy, 295, 304–305
  obesity and, 914, 931–932
  renal involvement in, 300
  studies, 249–251
Noonan's syndrome, 749
Noradrenergic agents, for obesity, 991, 996
Nuclear medicine studies in thyroid cancer, gallium, 100–101
  iodine, 94–99
  positron emission tomography, 101–102
  technetium, 93–94
  technetium sestamibi, 94
  thallium, 99–100
Nurses' Health Study (1995) of overweight, 896–897
Nutrition, differential diagnosis of primary undernutrition, 746
  growth hormone and, 557, 560, 561, 737, 766
Nutrition planning in obesity treatment, **955–964.** See also *Dietary therapy for obesity.*
  addition of dietary constituents that dilute energy, 960–961
  balanced lower calorie energy plans, 959
  characteristics and functions of energy-containing nutrients, 955–958
  classification of plans, 958–959
  as component of weight loss and maintenance program, 963
  diets lacking scientific basis, 962
  excess intake of one or more nutrients or foodstuffs, 960
  formula diets, 961–962
  reduction or elimination of one or more energy-containing nutrients, 959–960

Obesity, animal models, **781–813**
  behavioral therapy, **943–954**
  childhood, body composition and, **871–885**
  criteria for, 887–889, 965
  endocrinology of, **921–942**
  exercise for, **965–988**
  fat cells in, **847–870**
  food intake control in, **815–829**
  genetics, **801–813**
  in growth disorders, 745–746
  in growth without growth hormone syndrome, 655–656
  health hazards of, **907–919**
  medication for, **989–1004**
  nutrition planning in, **955–964**
  prevalence of, **887–905**
  surgery for, **1005–1027**
ob gene, 783–787, 806, 807, 821
Octreotide, for diarrhea, in diabetes, 374–375
Ocular complications in diabetes. See *Diabetes mellitus, retinopathy.*
Oligonucleotide hybridization, in detection of *RET* mutations, 8, 10–11
Opioids, in growth hormone system axis, 547
  hunger and, 824
ORG2766, for diabetic neuropathy, 343
Orlistat, for obesity, 1001
Osteoarthritis, in diabetes, 474
  obesity and, 916
Osteolysis, in diabetes, 475
Osteomyelitis, in diabetes, 454
Osteopenia, in diabetes, 473–474
Osteoporosis, glucocorticoids and, 708–709

post-traumatic, in diabetes, 476–477, 480
Ovaries, obesity and, 922–923
Overweight. See also *Obesity.*
criteria for, 887–889, 890, 892
prevalence, changes in, 893
in Europe, 898–901, 903
in particular US groups, 895
in prospective cohort studies, 895–898
Oxandrolone, in pubertal growth, 672–673
Oxyphilic (Hürthle) cell follicular neoplasms, fine-needle aspiration, 80, 82–83, 88, 89
surgical management, 124–125

PACAP, 548
Pain, in diabetes, abdominal, 370
in neuropathy, treatment, 344–347
Pancreas plus kidney transplantation, 312–313
Papaverine hydrochloride, for erectile dysfunction, 390–392
Papillary thyroid cancer, external beam radiation therapy, 143, 145
fine-needle aspiration, classic type, 73–77
cystic type, 77, 78–79, 87–88
follicular variant, 77, 79, 80
surgical management, 121–123
tall cell variant, 49–53
Parathyroid glands, in thyroidectomy, 131
Parkinson's disease, diabetes and, 331
PCR detection of *RET* mutations, 8–10, 12
Pediatrics. See *Children.*
Penile prosthesis, for erectile dysfunction, 392–394
Penis anatomy, 380
Pentagastrin test with calcitonin measurement, 12–14
Pentavalent technetium dimercaptosuccinic acid, in thyroid cancer imaging, 107, 109
Pentoxifylline, for diabetic nephropathy, 315
Peptide YY, in lipolysis, 862
Percutaneous transluminal coronary angioplasty, in diabetes, 432–433
Perforating dermatosis, in diabetes, 468
Pericytes, in diabetes, 256–257
Perinatal development, growth hormone secretion in, 552–554
Peripheral neuropathy, in diabetes, 332–347
Peritoneal dialysis, 310, 311
PET, in thyroid cancer, 101–102, 105
Pharmacotherapy of obesity. See *Medications for obesity.*
Phendimetrazine, for obesity, 991, 996
Phentermine, for obesity, 991, 993, 996, 998–1000
Phentolamine, for erectile dysfunction, 390–392
Phenylpropanolamine, for obesity, 991, 996
Phenytoin, for pain in diabetic neuropathy, 345
Pheochromocytoma, in MEN 2, management, 20
Photocoagulation, for diabetic retinopathy, 280–282
Physical activity. See also *Exercise.*
obesity and, 966–967
Pigmented pretibial papules, in diabetes, 465–466
Pima Indians, 234, 294
Pit–1, **523–540**
DNA binding and, 526, 528–529
growth hormone and prolactin gene activation and, 529
Pit–1 interactions on *GH* gene, 529–531
Pit–1 interactions on *Prl* gene, 531–532
PIT–1 gene activation, 533–534
PIT–1 gene mutations, 524–526, 527
Pit–1 protein and splice variants, 534–535
TSH-β gene activation and, 532–533
Pituitary adenylate cyclase–activating polypeptide, 548
Pituitary/adrenal axis, in obesity, 922
Pituitary-derived chondrocyte growth factor, in growth without growth hormone syndrome, 658
Pituitary gigantism, from growth hormone hypersecretion, 757
Pituitary gland, in growth hormone system axis, 544–545
Pituitary/gonadal axis, in obesity, 922–924
Pituitary–growth hormone–insulinlike growth factor–1 axis, in obesity, 924–927
Pituitary hormone deficiency, 523–524. See also *Pit–1.*
Plain films, in thyroid cancer, 102, 106
Plasminogen activator inhibitors, in diabetes, 426–427
Plastic surgery, in obesity, 1016–1017
Platelets, in diabetes, 427–428
Polycystic ovary syndrome, 746
Polygenic obesities, genetics, in rodents, 788–789
Polymerase chain reaction, in detection of *RET* mutations, 8–10, 12
Polyol hypothesis, in diabetic neuropathy, 338–339
Positron emission tomography, in thyroid cancer, 101–102, 105
Postnatal growth, insulin in, 644–645
Potassium, body, in childhood obesity, 878
Prader-Willi syndrome, 745, 803
genomic imprinting in, 509–511

Prednisone, growth suppression by, 704
Pregnancy, diabetic retinopathy in, 279
  insulin-like growth factor binding proteins proteases in, 608
  thyroid cancer and, 41–43
Prevalence of obesity, **887–905**
  criteria for overweight and obesity, 887–889
  cross-sectional, prospective, and retrospective approaches, 889–890
  determination of, 889
  discussion, 901–904
  in Europe, 898–901
  in particular US groups, 895
  in prospective cohort studies, 895–898
  study populations, 890
  in US adults, 890–895
Prl gene, Pit–1 interactions on, 531–532
Progeria, 749
Prolactin, in erectile dysfunction, 386, 389
  gene expression, Pit–1 and, 523, 525, 527, 531–532
  in growth without growth hormone syndrome, 657
  in obesity, 927–928
Prostaglandin E_1, for erectile dysfunction, 390–392
Prostaglandins, in lipolysis, 862
Prostate hyperplasia, 606, 608
Prostate-specific antigen (PSA), 606, 608
Protein, in nutrition planning, 955–956, 959
  restriction in diabetic nephropathy, 302–303
Protein kinase C, in diabetes, 259–260, 284–285
Proteinuria, in diabetes, 223–224, 226–227, 228
Proximal motor neuropathies, in diabetes, 334
Pseudoachondroplasia, 690
Pseudoacromegaly, 653–654
Pseudomonas aeruginosa, 469
Psychosocial function, obesity and, 917
PTCA, in diabetes, 432–433
PTHrP receptor, in chondrodysplasia, 692–693
Puberty, **665–681**
  bone age and, 744–745
  bone mineralization in, 673–675
  delayed, 750–751
  growth at, 665
  growth disorders and, clinical observations, 670–671
  growth hormone and sex steroid interactions in, 670
  growth hormone/insulin-like growth factor I axis in, 666–669
  growth hormone secretion in, 555
  hormonal control, 666–669
  insulin in, 635
Pulmonary function, obesity and, 913

Quetelet index, 874–875

Rabson-Mendenhall syndrome, 645
Radiation exposure, thyroid cancer from, **181–195**, 197–198. See also *Chernobyl accident*.
  cancer genes and, 187–188
  dose-response relationships, 185–187
  patient evaluation, 188–190
  patient management, 190–192
  risks in children, 28–29
  sources, 182–184
  susceptibility, 187
Radioactive iodine ablation, in pediatric thyroid cancer, 32, 34–35
  follow-up scans, 38
  risks, 35–37
Radioactive iodine imaging, in thyroid cancer, 94–95, 105
  common isotopes, 95–96
  controversies, 98–99
  false-positives, 98, 99
  for follow-up, 96–98
  of medullary carcinoma, 107
Radiography, plain film, in thyroid cancer, 102, 106. See also *Imaging in thyroid cancer*.
Radiotherapy. See also *External beam radiation therapy; Radioactive iodine ablation*.
  growth effects of, 737–739
    central, 731–733
    peripheral, 733–734
Reactive perforating collagenosis, in diabetes, 468
Recurrent laryngeal nerve, in thyroidectomy, 129–131
Reflex sympathetic dystrophy, in diabetes, 476–477, 480
Reinforcement, in obesity therapy, 945–946
Renal cell carcinoma, metastatic to thyroid, fine-needle aspiration, 86, 89
Renal disease in diabetes, **293–324**
Renal failure, chronic, growth hormone and, 559, 753, 760–761
Resistance to thyroid hormone, clinical overview, 721, 723
  effect of thyroid hormone on growth in, 724–725, 728
  molecular basis, 723
  relationship to growth, 723, 726–728
Respiration chambers, in energy expenditure measurement, 836–838
Respiratory system, obesity and, 913

Resting metabolic rate, in energy expenditure, 832, 834, 835
Restriction enzyme analysis, in detection of *RET* mutations, 8
RET proto-oncogene, 2, 40–41
  Hirschsprung's disease and, 6
  molecular techniques for detection of mutations, errors sources in genetic testing, 11–13
    in MEN 2A and familial medullary thyroid carcinoma, 7–11
    in MEN 2B, 11
    in sporadic medullary thyroid carcinoma, 11
  mutations and neoplasia, 6–7
  mutations in MEN 2 and medullary thyroid carcinoma, 2–6
Revascularization, in diabetes, 432–434
Rhinocerebral mucormycosis, in diabetes, 332
Rodents, genetics of obesity in, 806–810
Roux-en-Y gastric bypass, for obesity, 1011–1012
RTH. See *Resistance to thyroid hormone.*
Russell-Silver syndrome, 515, 749

S phase of cell cycle, 493, 496–497
Satiation and satiety, putative signals for, 817–824
Schmid metaphyseal chondrodysplasia, 687
Scleredema, diabetic, 466
Scleroderma diabeticorum, 475
SED, 685
Sedentary lifestyle, health hazards of, 910
  in obesity, 966–967
Segregation analysis, in obesity, 804–805
Self-monitoring, in obesity therapy, 946–947
Sensory feedback, in eating behavior, 817–818
Sensory polyneuropathies, in diabetes, 333
Serotonergic agents, for obesity, 991, 997–998
Seventh-Day Adventist Study (1991) of overweight, 895–896
Sex hormone–binding globulin, 922–923
Sex steroid hormones, growth hormone interactions with, in bone mineralization, 673–676
  clinical observations, 670–671
  in infancy and childhood, 669–670
  in puberty, 670
  role of androgens versus estrogens, 671–673
  in puberty, 666
Sexual dysfunction. See *Erectile dysfunction.*
Shoes, therapeutic, in diabetes, 456
Short stature, 747–748
  attenuated growth pattern, 751–753
    diagnosis, 753–754
  classification, 748
  delayed growth and puberty, 750–751
  growth hormone therapy, 761–764
  intrinsic shortness, 749–750
Shoulder-hand syndrome, in diabetes, 476–477, 480
Sibutramine, for obesity, 1001, 1002
Silent ischemia, in diabetes, 431–432
Single-strand conformational polymorphism analysis, in detection of *RET* mutations, 8, 10
Sipple's syndrome, 755
Skeletal disease, in diabetes, 473–474
Skeletal injury from irradiation, 733–734
Skin, obesity and, 916
Skin disorders in diabetes, **463–472**
Sleep, growth hormone secretion in, 557
Sleep apnea, obesity and, 913
Small cell carcinoma of thyroid, fine-needle aspiration, 86
Social supoprt, in obesity, 947
Sodium/potassium adenosine triphosphate, in diabetes, 258
Somatomedin hypothesis, 573–574, 617–619, 767
Somatomedins, in growth without growth hormone syndrome, 650–651
Somatostatin, 543–544, 551
Somatostatin receptor imaging, in thyroid cancer, 109–110
Somatotroph, growth hormone–releasing effects on, 548–551
  somatostatin effects on, 551
Sorbitol, in diabetes, 283–284
Sotos' syndrome, 755, 757
SOX9, 693–694
Spinal cord abnormalities, in diabetes, 332
Spinal injury from irradiation, 733–734
Spondyloepiphyseal dysplasia, 685
Squamous cell carcinoma of thyroid, 56–59
SRIF, 543–544, 551
Staphylococcus aureus, 469
Steroids, adrenal, in obesity, 794–795
  growth suppression by, **699–717**
Stickler dysplasia, 685, 686, 687
Stiff hand syndrome, in diabetes, 477, 480
Stimulus control, in obesity therapy, 945
Stockholm Diabetes Intervention Study, 246, 247
Stress, growth hormone secretion in, 557
Stroke, hyperglycemia and, 326–328
Substance P, in diabetic neuropathy, 346
Substrate balance, in obesity, 842–843
Suction-assisted lipectomy, for obesity, 1017
Sudeck's atrophy, in diabetes, 476–477, 480
Sulfonylureas, in diabetes, cutaneous reaction, 469–470

Surgery for obesity, **1005–1027**
advantages of long-term surgical weight loss, 1019
complications, 1019
indications, 1017–1018
operative and postoperative considerations, 1018–1019
outcome, 1019–1020
preoperative assessment, 1018
procedures, biliopancreatic bypass, 1010–1011
gastric balloon, 1015–1016
gastric bypass, 1011–1013
gastroplasty, 1013–1014
jaw wiring and waist cord, 1016
jejunoileal bypass, 1006–1010
plastic surgery, 1016–1017
vagotomy, 1014–1015

Tall cell variant of papillary thyroid cancer, 49–53
Tallness, excessive, 754, 756
acclerated growth, 757
advanced growth, 755, 757
classification, 755
intrinsic tallness, 754–755
Tamoxifen, 673
Tarsal tunnel decompression, in diabetic neuropathy, 347
Technetium dimercaptosuccinic acid, pentavalent, in thyroid cancer imaging, 107, 109
Technetium–99m imaging, in thyroid cancer, 93–94, 104
Technetium sestamibi imaging, in thyroid cancer, 94
Testes, obesity and, 923–924
Testicular feminization, 671
Testosterone, lipoprotein lipase and, 853–854
in obesity, 923–924
in pubertal growth, 671
Testosterone therapy, in diabetes, 388–389
TGF-β, in thyroid cancer, 169–170
in vascular dysfunction, in diabetes, 264
Thallium imaging, in thyroid cancer, 99–100
medullary carcinoma, 108, 109
studies, 95
uses, advantages, and disadvantages, 105
Thallium scintigraphy, in diabetes, 308
Thanatophoric dysplasia, 688
Thermic effect of food, 834, 836
Thick skin, in diabetes, 466–467
Thrombolytic therapy, in diabetes, 430–431
Thyroglobulin, in thyroid cancer, 163–164
scanning, in pediatric thyroid cancer, 37–38

Thyroid cancer, in childhood, pregnancy, and Graves' disease, **27–48**
in children after Chernobyl accident, **197–211**
classification and incidence, 121
diagnosis. See *Fine-needle aspiration of thyroid; Imaging in thyroid cancer.*
external beam radiation therapy, **141–157**
from external radiation, **181–195**
fine-needle aspiration and diagnosis, **69–91**
genetic screening in medullary thyroid carcinoma and MEN 2, **1–26**
host immunologic factors in, 160–161
imaging, **93–113**
immunology, **159–179**
antigencity of thyroid epithelial cancers, 162–164
cancer as molecular disorder, 159
cytokine interactions on thyroid cancer cells, 166–170
immunity in prevention/control of thyroid cancer, 160–162
potential immunotherapeutic interventions, 170–174
thyroid cancer–specific antigens, 164–166
immunotherapy, potential interventions, 170–174
prior attempts, 161–162
surgery, **115–139**
anaplastic thyroid carcinoma, 126
evaluation of thyroid nodule, 116–119
Hürthle cell carcinoma, 124–125
indications, 119–120
lymph node dissection, 123–124
medullary thyroid carcinoma, 125–126
papillary and follicular carcinoma, 121–123
postoperative management, 133–134
preparation, 127
procedure, 128–133
rare tumors, 127
selection of operation, 120
surgical considerations and approach, **115–139**
unusual neoplasms, **49–68**
Thyroid cancer in children, after Chernobyl accident, **197–211**
clinical experience and accrual of cancers, 201–205
epidemiology, 205–208
ongoing and future inquiries, 208–209
diagnostic and treatment paradigm, 38–39
follow-up, 37–38
incidence, 27–28
ionizing radiation risks, 28–29
medullary thyroid carcinoma, 39–41

nodules, 29–30
postoperative management algorithm, 40
radioactive iodine therapy, 34–37
risk factors stratification, 32–33
surgical extent, 37
thyroid hormone effect on bone mineral density, 34
thyroid hormone suppression and, 33–34
treatment and outcome, 30–32
in United States from 1900 to 1970, 198
Thyroidectomy. See also *Thyroid cancer, surgery.*
indications, 119–120
in medullary thyroid carcinoma, 18–20
in pediatric thyroid cancer, 32, 37, 41
postoperative management, 133–134
preparation, 127
procedure, 128–133
Thyroid hormone, action of, 720
growth effects, **719–730**
in pediatric thyroid cancer, 32–34
resistance, 721–728
Thyroid nodules, in children, 29–30
management algorithm, 39
evaluation, 116–119
in patients with history of irradiation, 190–192
in pregnancy, 41–42
Thyroid peroxidase, 163, 164
Thyroid-stimulating hormone, in obesity, 927
Thyroid-stimulating hormone receptor, in thyroid cancer, 162–163
Thyroid-stimulating hormone suppression, in irradiated patients, 192
in pediatric thyroid cancer, 33–34
Thyrotropin, gene expression, Pit-1 and, 523, 524–525, 527, 532–533
Thyrotropin-releasing hormone, 547–548
TNF, lipoprotein lipase and, 854
TNF-α, in obesity, 932–933
in thyroid cancer, 167, 173
Toes, gangrene of, 450–451
Tolrestat, for diabetic neuropathy, 342
Total daily energy expenditure, 831
measurement, 836–842, 966–967
Total parenteral nutrition (TPN), growth hormone and, 766
Tramadol, for diabetic neuropathy, 346–347
Transcription factors, in thyroid cancer, 164–165
Transforming growth factor β, in thyroid cancer, 169–170
in vascular dysfunction in diabetes, 264
Transgenic models of obesity, 789–790
TRβ gene, 723
TRH, 547–548
Triglycerides, synthesis of, 856–857
Truncal neuropathy, in diabetes, 335–336
TSH, in obesity, 927
Pit-1 and, 523, 524–525, 527, 532–533
TSH-β gene, Pit-1 and, 532–533
tub gene mutation, in obesity, 788, 806–807
Tumorigenesis, insulin-like growth factors and, 587
Tumor-infiltrating lymphocytes, in thyroid cancer, 171
Tumor necrosis factor, lipoprotein lipase and, 854
Tumor necrosis factor α, in obesity, 932–933
in thyroid cancer, 167, 173
Turner syndrome, growth hormone in, 669–670, 671
growth hormone therapy, 761, 762
male, 749
short stature in, 749
Twin studies of obesity, 803

Ulcers, foot, management, in diabetes, 452–455
post-healing, 456
topical treatment, 455–456
in necrobiosis lipoidica diabeticorum, 465
Ultrasonography, in thyroid cancer, 102–103, 106, 117
Undernutrition, 745–746
Uniparental disomy, 507–508, 513, 515
UPD7mat, 515

Vacuum erection devices, 389
Vagotomy, for obesity, 1014–1015
Vascular endothelial growth factor, in diabetes, 264, 286
Vascular surgery, for erectile dysfunction, 394
Vasoactive agents, for erectile dysfunction, 389–392
VEGF, in diabetes, 264, 286
Vein grafts to dorsalis pedis artery, 442
Very low calorie diets, 950, 958, 961–962, 1001
Visual loss, in diabetes, 275–277
Vomiting, in diabetes, 363–364

Waist cord, for obesity, 1016
Weight gain, diabetes and, 914
health hazards of, 910
after obesity treatment, 951–952
Weight loss, exercise in, initial weight loss, 968–976
maintenance, 976–978

Weight maintenance, in behavioral therapy for obesity, 947–948
after modified fast, pharmacotherapy in, 1001
Wilms' tumors, 512, 515
Wisconsin Epidemiologic Study of Diabetic Retinopathy, 245–246
Wound healing impediments, in diabetes, 457

Yellow skin, in diabetes, 468
Yohimbine hydrochloride, for erectile dysfunction, 388

Zopolrestat, for diabetic neuropathy, 342